ABSTRACT

Introduction

Metabolic-associated fatty liver disease (MAFLD) is the most common liver disease globally, and affects about a quarter of the general population. Autoimmune hepatitis (AIH) is a severe (sometimes fatal) liver disease that affects children and adults, with a rising prevalence. Thus, not surprisingly, both conditions can frequently coexist, with potential synergistic impact on the course of the disease and response to therapy of both entities.

Areas covered

In this work, the authors aimed to provide a narrative updated review on this interaction, diagnosis, and management of MAFLD/AIH and the current challenges.

Expert opinion

Clarifying the nature of the complex interaction between the two diseases was hampered by a myriad of factors, particularly the previous diagnosis of exclusion for fatty liver disease associated with metabolic dysfunction. The recent redefinition of fatty liver disease that led to the development of positive diagnostic criteria for MAFLD has the premise to help in circumventing some of these challenges.

中文翻译：

---

代谢相关性脂肪肝和自身免疫性肝炎：一种被忽视的相互作用

摘要

介绍

代谢相关性脂肪肝病 (MAFLD) 是全球最常见的肝病，影响约四分之一的普通人群。自身免疫性肝炎 (AIH) 是一种影响儿童和成人的严重（有时是致命的）肝脏疾病，患病率不断上升。因此，毫不奇怪，这两种情况可以经常共存，对疾病的进程和对两种实体的治疗反应具有潜在的协同影响。

涵盖的领域

在这项工作中，作者旨在就 MAFLD/AIH 的这种相互作用、诊断和管理以及当前的挑战提供一个叙述性更新的综述。

专家意见

澄清这两种疾病之间复杂相互作用的性质受到无数因素的阻碍，特别是先前排除与代谢功能障碍相关的脂肪肝疾病的诊断。最近对脂肪肝疾病的重新定义导致了 MAFLD 阳性诊断标准的发展，其前提是有助于规避其中一些挑战。